Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Milk-Borne Transmission of HIV-1C in Botswana ("Mashi")
Brief Summary: The purpose of this study is to find the most effective and safe treatment to prevent the passage of HIV from an infected mother to her baby.


Options:
A: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nelfinavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): 1, 2
C: Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): N/A
D: Arm Label: Deferred therapy Arm; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 40 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: Early therapy for 96 weeks; Type: EXPERIMENTAL; Interventions: Drug: Abacavir sulfate, Drug: Didanosine, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir sulfate; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Didanosine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Deferred therapy Arm, Early therapy for 40 weeks, Early therapy for 96 weeks

Answer: A